Drug Profile


Alternative Names: GM-1070; GMI-1070; PF-06460031; PF-6460031

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator GlycoMimetics
  • Developer GlycoMimetics; Pfizer
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Preclinical Haematological malignancies

Most Recent Events

  • 01 Jan 2017 Pfizer initiates enrolment in a phase I trial for Health volunteers in USA (NCT02998099)
  • 21 Dec 2016 Pfizer plans a phase I pharmacokinetics trial in Healthy volunteers in USA (IV) (NCT02998099)
  • 01 Sep 2016 Pfizer initiates a phase I pharmacokinetics trial in Healthy volunteers and subjects with hepatic impairment in USA (NCT02871570)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top